Top Tech Companies (2,068)
Don't see your company?
Create a company profile
We are hiring: https://histowiz.workable.com/ About HistoWiz HistoWiz is an innovative company dedicated to accelerating pathology-based research. HistoWiz provides fast, global access to digital whole-slide images, online collaboration tools, low-cost data management, and experimental pathology expertise. The web-based platform accelerates information exchange among medical scientists and research pathologists. HistoWiz's mission is to fight cancer cooperatively instead of individually by connecting scientists and pathologists for online collaboration. The HistoWiz advantage We help your lab minimize the cost of research and maximize research productivity by providing the most efficient service for scientists to analyze experimental pathology specimens. We believe that scientists should spend their time on results interpretation rather than repetitive tissue cutting. How does it work? HistoWiz accepts formalin-fixed specimens by mail for tissue processing services. To expedite delivery of results and to facilitate global collaboration, HistoWiz offers whole-slide imaging and pathology services, allowing researchers to remotely and instantly view high-magnification images of their specimens via a secure, cloud-based “virtual microscope” on any computer or mobile device without downloading any software or gigabyte-sized files.
SmartAnalyst is focused on supporting Bio-Pharma Innovation, with a mission to drive pipeline and portfolio value for global pharmaceutical and biotech companies. We provide Consulting services, Health Economic and Real World Evidence solutions, and Insights that are compelling, strategic and actionable. Founded in 2000 and a part of the UDG Healthcare group since 2018. Our three pillars of Strategy, Value and Insights are aimed at identifying and commercializing novel innovative therapies to improve patient outcomes and garner market success, providing compelling clinical and cost benefit evidence to secure advantageous reimbursement and access to patients, and data driven insights into future market dynamics to develop forward looking strategies for clinical differentiation and success. We have worked across all major therapeutic areas including oncology, immunology, neurosciences, cardiovascular and rare diseases. Oncology is the cornerstone of our consulting business.
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product, Tru Niagen® — available at www.truniagen.com and through partnerships with global retailers and distributors. For company news, press releases, and more, visit www.chromadex.com. ChromaDex® is a publicly traded company (NASDAQ: CDXC).
GeneBiology develops a patented new drugs for serious diseases using the 505(b)(2) regulatory pathway.
BioMADE is a new Manufacturing Innovation Institute sponsored by the U.S. Department of Defense. BioMADE is building a sustainable, domestic, end-to-end bioindustrial manufacturing ecosystem to secure America’s future through innovation, education, and collaboration. As an independent nonprofit, public-private partnership, BioMADE has the mission and flexibility to propel new biotechnology products from the laboratory to the commercial market.
Every day millions of people feel the impact of our intelligent devices, advanced analytics and artificial intelligence. As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world. We embrace a culture of respect, transparency, integrity and diversity.
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.
Help us shape the future of sports medicine! Breg provides premium, high-value sports medicine products and services that advance orthopedic patient care. From pioneering cold therapy products and innovative bracing to caring customer service and award-winning orthopedic practice solutions, Breg delivers a 360°customer experience unmatched in the industry. Breg is a company of Water Street Healthcare Partners. Founded in 1989, Breg offers cold therapy, knee, shoulder, spine, elbow/wrist, foot/ankle bracing and orthopedic practice solutions. The Company’s products are sold through more than 100 distributors in 36 countries. Breg is based in Carlsbad, CA. For two decades, Breg has transformed orthopedic care with industry-leading products. Breg is the leader in motorized cold therapy, selling over two million Polar Care® units. The Fusion® family of functional knee braces combine sleek, lightweight design with exceptional comfort and fit. Breg's SlingShot® 3 Shoulder Brace is the industry's first brace that off-loads pressure from the neck, greatly improving patient comfort. The Freestyle™ OA is the world's first wrap-around knee brace for osteoarthritis. Breg's newest products include the T Scope® Premier Knee brace and the T Scope Premier Hip brace which use Breg's easy-to-use hinge technology to manage patient mobility while maintaining patient comfort.
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Echelon Biosciences builds tools and reagents for life science research and drug discovery.
Visionary Pharmaceuticals is a biotechnology company developing first-in-class drugs for unmet medical needs in cancer and inflammation.
The mission of Alume Biosciences is to make our proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit. Learn how you can help us move surgery into the light.
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.
Stereotaxis develops robotic cardiology instrument navigation systems that enhances the treatment of arrhythmias and coronary diseases.
MediciNova is a biopharmaceutical company that acquires and develops novel, small-molecule therapeutics.
Primal Therapies is a biotechnology company that specializes in the fields of biofilm management and healthcare.
Cylene Pharmaceuticals discovers, develops and commercializes small molecule drugs that target nucleolus and kill cancer cells.
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies
Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.
Femta Pharmaceuticals is a biotechnology company that develops protein therapeutics.
